Choosing hypoxia and metabolic antibodies: why a hif antibody detects a protein that is destroyed in seconds of reoxygenation, what an slc1a5 antibody and an slc7a11 antibody demand as multipass transporters, where a transferrin receptor antibody, a plain transferrin antibody and an ogt antibody sit, and the lysis that decides all of it

Handling a target that disappears

1. Lyse inside the chamber, or accept the loss. The hypoxia factor is hydroxylated and degraded rapidly once oxygen is available, so plates taken to a bench lose most of the signal before lysis. Lysing inside the hypoxia chamber, or working fast on ice with the lysis buffer already prepared, is the difference between a band and nothing.
2. Use a proteasome inhibitor arm as the positive control. Blocking degradation stabilises the factor and gives a strong band that shows the antibody and the blot work. It also proves that a missing band in the experimental arm is biology rather than handling.
3. Know that a nuclear fraction reports the active pool. The factor acts in the nucleus and the whole-cell level includes protein on its way to destruction. Fractionating, or imaging a nuclear signal per cell, reports the pool that is doing something.
4. Treat the transporters as multipass membrane proteins. Amino acid and other solute transporters aggregate when boiled and need a detergent that keeps the epitope. Denature at a lower temperature, prepare membranes rather than whole lysate, and use a genetic negative because background is high.
5. Use a modification-aware reagent where the target is a modifier. Enzymes that add a sugar or another modification are read through their substrates as much as through their own level, so a total antibody tells you the enzyme is present while a substrate-modification antibody tells you it is working.

Chemical hypoxia mimetics and their limits

Compounds that stabilise the factor by inhibiting its hydroxylases are convenient and are not hypoxia: they stabilise the protein without changing oxygen tension, so the rest of the cell's response differs. Use them as controls and be explicit about the distinction.

Where the biology of low oxygen matters rather than the factor alone, a real chamber with measured oxygen tension is the experiment, and the tension should be recorded rather than assumed from the setting.

Downstream targets as the honest readout

Transcriptional targets of the pathway accumulate over hours and are far easier to measure than the factor itself. Where the question is whether the pathway ran, a target transcript or protein is more robust than chasing a protein that disappears.

Measuring both, with the factor as the immediate readout and a target as the durable one, is what makes a hypoxia experiment convincing rather than fragile.

Common questions

Why does my hif antibody show no band from hypoxic cells?

The protein is degraded within minutes of reoxygenation, so it is usually lost between the chamber and the bench. Lyse inside the chamber, or work fast and cold, and run a proteasome inhibitor arm as a positive control.

What proves the blot would have worked?

A proteasome inhibitor arm. Blocking degradation stabilises the protein and gives a strong band, which shows the reagent and the transfer are fine and that the experimental result is biology.

Why do my transporter blots look like nothing?

Multipass transporters aggregate when boiled and stay in the well. Denature at thirty seven or seventy degrees, prepare membranes rather than whole lysate, and use a knockdown as the specificity control.

Should the hypoxia factor be measured in the nucleus?

Where the question is about activity, yes. The whole-cell pool includes protein destined for degradation, so a nuclear fraction or a per-cell nuclear intensity is a better proxy for the active pool.

Browse by service class

• Compare Gene synthesis on advertised prices